Introduction
The tumor suppressor p53 plays a key role in preventing malignant transformation and inhibiting the development of cancer. In response to cellular stress, the p53 pathway triggers gene transcription, which can result in cell cycle arrest, apoptosis, and DNA repair and/or senescence (1) . The dysregulation of the p53 pathway is the most frequent alteration detected in a broad range of human cancers, and approximately half of these cancers have been determined to carry mutated TP53 (2) . Another mechanism by which p53 function may become lost is the overexpression of MDM2. Under nonstress conditions, the E3 ubiquitin ligase MDM2 is a negative regulator that directly binds to and inhibits p53 activity by targeting p53 for ubiquitin-dependent degradation (3, 4) .
Therefore, MDM2 overexpression results in reduced p53 levels, inadequate cell growth arrest, and apoptosis. Accordingly, disrupting the binding of MDM2 to a functional p53 can be expected to restore p53-dependent cellular arrest and apoptosis.
The nutlin family of MDM2 antagonists was designed to disrupt p53-MDM2 binding (5-7), thereby stabilizing and activating p53. In preclinical studies, the nutlin family member RG7112 promoted the reactivation of the p53 pathway to elicit growth arrest and apoptosis in tumor cells where MDM2-gene amplification or other oncogenic drivers has allowed evasion of p53-activated cell death (8) . However, during RG7112 clinical testing, there were tolerability challenges with prolonged daily oral administration of RG7112 (≥ 10 consecutive days in patients), including grade 3/4 vomiting, neutropenia, and thrombocytopenia (9) . Therefore, optimization of the schedule of administration, including pursuing intermittent dosing, is an important consideration for further clinical development of MDM2 inhibitors. The pyrrolidine RG7388, which has the same mechanism of action as the imidazoline RG7112, is a more potent and selective second-generation MDM2 inhibitor (8, 10) . In preclinical studies, RG7388 effectively activated the p53 pathway in SJSA1 cells and induced tumor growth inhibition (TGI) in correlative xenografts in nude mice at significantly lower doses and exposures than RG7112 (10, 11) . These results suggest the potential of achieving a clinical benefit at significantly lower drug concentrations with RG7388 and indicate that it should be possible to achieve a decrease in the severe toxicities that limited the less potent RG7112.
As RG7112 had poor tolerability when given daily, we sought to determine if RG7388 could be dosed intermittently to circumvent the need for daily administration.
To better understand the scheduling requirements for optimal RG7388 antitumor activity, a model-based approach was undertaken (12) . First, a dynamic pharmacokineticpharmacodynamic (PKPD) model was developed to investigate how the pharmacokinetics of RG7388 are related to the time course of the antitumor effect in SJSA osteosarcoma xenografts in mice (Fig. 1, step 1and 2) . Second, the model was used to prospectively predict intermittent and continuous dosing regimens that would result in tumor stasis (Fig. 1, step 3 ). This allowed for the testing of dosing hypotheses by comparing a priori predicted responses to the actual observed tumor growth profile ( Fig.   1 step 4) . Given that both p53 and MDM2 have short half-lives, 2 hypotheses were that continuous suppression of the p53-MDM2 interaction would be required for optimal antitumor activity, or alternatively, that stabilization and activation of p53 and subsequent apoptosis, triggers a sustained anti-tumor effect. The first hypothesis would be consistent with the need for continuous dosing and assumes that the PD is directly linked to the PK, 
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whereas the second hypothesis implies that intermittent dosing should be sufficient to elicit a robust antitumor response, while potentially reducing the occurrence of severe adverse events associated with the prolonged continuous administration of RG7112 (Fig.   1, step 5 ).
Materials and Methods
In vitro testing in cancer cell lines were seeded at densities identified for best growth for a 5-day assay in 96-well plates in normal growth media. Serial dilutions of RG7388 (1 to 3 in fresh media) starting at 300 µM were applied to wells (1 to 10) in triplicate for a final concentration range of 0.01-30 µM and control wells were treated with 0.3% DMSO equivalent to DMSO at the highest RG7388 concentration. Cell respiration, as an indicator of cell viability, was measured by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan as previously described (5).
Percent apoptosis was determined as described in Tovar et al (8) . 
Pharmacokinetic analysis
To determine RG7388 plasma concentrations, blood samples were collected from female mice during in vivo antitumor studies. In each treatment group, on the first and/or last dosing day, blood samples (generally n = 2/time point) were collected at various predetermined time points ranging from 0.5 to 24 hours after the last dose.
Pharmacokinetic assessment was performed via noncompartmental analysis using Tumor measurements and weights were taken 2-3 times per week. TGI was calculated from percent change in mean tumor volume compared with the control group. Average percent weight change was used as a surrogate endpoint for tolerability in the experiment.
Animals in each group were continuously followed beyond the last day of treatment to
Research. [(median day of death in treated tumor-bearing mice) -(median day of death in control tumor-bearing mice)]/Median day of death in control tumor-bearing mice × 100.
Statistical analysis was performed as previously described (8).
RG7388 was administered as an amorphous solid dispersion microbulk precipitate powder containing 30% drug substance and 70% Hydroxypropyl methylcellulose acetate succinate polymer that was reconstituted immediately before administration as a suspension in Klucel/Tween, and remaining suspension was discarded after dosing.
Modeling and simulation
1. The PKPD model structure:
For PKPD modeling, plasma PK was fitted to a 1-compartmental model assuming nonlinear bioavailability and a first-order absorption and elimination rate constant. The differential equations and initial conditions for the PK are as follows: The full PKPD model assumes that the drug effects of RG7338 are delayed relative to the observed antitumor effect. This was described by using a signal distribution model based on the model proposed by Lobo and Balthasar (13) .
The model structure is shown in supplemental figure S1, and the differential equations and initial conditions for the PKPD are as follows:
Where R represents the tumor volume, kg the exponential tumor growth rate, and w 0 initial tumor volume [mm 3 ], and tau [h] represents the mean transit time equal for each compartment. Drug effect E was described by a linear drug effect model.
PKPD parameter estimation:
PKPD parameter estimation was done using a nonlinear mixed effect modeling software Monolix, 4.3.1 (Lixoft, France). For the PK, residual errors were assumed to be proportional to the predicted concentrations and a proportional error model was selected.
For the PD, an additional + proportional error model was selected. Diagnostic plots were 
Immunohistochemistry and image analysis
Formalin-fixed, paraffin-embedded histological samples from xenografts were used for immunohistochemical analysis using the Ventana Discovery XT platform (Ventana Medical System, Tucson, AZ). Briefly, 5-micron tissue sections were stained using rabbit monoclonal antibodies anticleaved PARP-1 (Cell Signaling Technology, Danvers, MA), and anti-Ki-67 (Thermo Fisher Scientific, Kalamazoo, MI). Tissues were pretreated using heat-induced epitope retrieval, and a 3-step biotin-streptavidin-HRP detection 
Results

RG7388-induced apoptosis in SJSA osteosarcoma cells is delayed relative to drug exposure but does not require continuous treatment
Recent data demonstrated that RG7388 induces p53 pathway activation and in vivo activity at much lower concentrations (≈25%) and exposures (≈7%-10%) than RG7112 (8, 10) . Therefore, we initiated our experiments at these lower doses.
To investigate the dosing schedule requirements for RG7388-induced apoptosis of the MDM2-amplified SJSA1 osteosarcoma line, cells were treated with a single dose of RG7388 (300 nM or 1.8 M) for 16 hours as established in previous continuous-dose experiments (10) . These concentrations were chosen based on antiproliferative activity as measured by an MTT assay and represent the average IC 90 and 6 times the average IC 90
Research. Table S1 ). At 24 hours and 48 hours after washout of RG7388, apoptosis was determined by positivity for annexin V. A significant apoptotic response over the control was induced with both the single 300 nM and 1.8 M concentrations of RG7388 (P < 0.005), with the 1.8 µM concentration providing optimal response ( Fig. 2A) . Induction of apoptosis was stronger at 48 hours post washout compared with 24 hours post washout.
As comparable levels of apoptosis were achieved with 48 hours of continuous RG7338 dosing at the same concentrations (10), these in vitro results suggest that once the apoptotic component of the p53 pathway is activated in tumor cells by the MDM2 antagonist RG7388, continuous exposure to RG7388 is not required to sustain this activation.
Western blot analyses of p53, MDM2, and p21 protein levels (Fig. 2B ) at the optimal apoptosis response level of 1.8 µM further supported the idea that continuous dosing was not required for sustained RG7388 activity. P53 protein levels were increased 16 hours after a single treatment with RG7388. When p53 levels increase, the transcription of its targets should increase. Accordingly, the protein levels of MDM2 and p21 were also elevated. While stabilized p53 protein did decrease 4 hours after washout, p53 levels then persisted and remained elevated compared with the control for at least 48 hours post washout. In contrast, MDM2 and p21 protein level increases were lost by 24 and 48 hours, respectively, post washout. These patterns are consistent with previous Collectively these data along with efficacy data were utilized in the design of our modeling and simulation.
PKPD modeling to investigate the relationship between RG7388 exposure and time course of antitumor effect
The in vitro data suggest that the drug effect is delayed and then maintained relative to the drug exposure even after washout. To further understand how the pharmacokinetics of RG3788 is linked to the antitumor effect, we conducted a PKPD study in SJSA osteosarcoma xenograft-bearing mice. In this study, the tumor growth profiles and the respective plasma PK profiles were monitored over a 21-day period for inclusion in the model. Animals were given oral doses of RG7388 at 1.11, 3.33, 10, or 30 mg/kg once daily, 50 mg/kg once weekly, or 50 mg/kg twice weekly (Mon/Wed). The highest doses investigated were of predetermined tolerability based on pilot experiments (data not shown). While the once-daily dose of 30 mg/kg of RG7388 (total 210 mg/kg/wk) appeared to be the most effective dose at inhibiting tumor growth (> 100% TGI with 9 partial regressions), the 50 mg/kg of RG7388 given twice a week (total 100 mg/kg/wk) was equivalent by statistical analysis ( Fig. 2C ; 96% TGI with 3 partial regressions; P > 0.05). Additionally, 50 mg/kg of RG7388 given once a week (50 mg/kg/wk) elicited an equivalent TGI as 10 mg/kg of RG7388 given once daily (70 mg/kg/wk; 79% TGI versus 77% TGI, respectively; P > 0.05), despite being a lower total weekly dose. Therefore, 
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intermittent dosing was equivalent to continuous administration for RG7388-mediated TGI in this xenograft model.
RG7388 exposure levels after multiple oral doses in female mice
RG7388 exposure levels were determined in the mice after the last dose of RG7388 (ie, day 21). The exposures increased greater than dose proportionally between 1.11 and 3.33 mg/kg, and less than dose proportionally between 3.33 and 50 mg/kg ( Fig.   3A and Supplementary Figure S2) . The concentration time profiles were well describe by a one-Compartmental PK model ( Supplementary Fig. S2 and S3 ).
The dose-exposure response relationship was characterized quantitatively and a mechanism-based PKPD model was fitted simultaneously to the observed individual PK and PD data of all groups (Fig. 3A , PKPD parameter estimates Supplementary Table S2 ).
The model separates system-related properties (tumor size and tumor growth rate) from drug related properties (potency, drug-induced kill rate) and incorporates the following assumptions: (1) MDM2 is amplified, resulting in the inhibition of p53-induced apoptosis in the SJSA xenograft tumors, (2) proliferation of SJSA cells thereby becomes the predominant process, resulting in unperturbed tumor growth, (3) after administration of RG7388, MDM2 is sufficiently blocked from negatively regulating p53, which in turn induces cellular growth arrest and apoptosis, and (4) the delay in tumor response to drug effect is due to signal transduction processes intervening between drug-receptor interaction and the killing event with the killing effect occurring through a signal transduction cascade (14) . Similar modeling approaches have been reported to assess antitumor effect in xenograft mice (15, 16) . These models allow for the estimation of a concentration resulting in tumor stasis. The drug effect of RG7388 is assumed to depend (Fig. 3A) .
Model-based approach to select intermittent dosing regimens targeting tumor stasis
This model was then used to select intermittent dosing regimens that are predicted to result in tumor stasis. The PKPD model quantitatively characterized how the pharmacokinetics of RG7388 is linked to the antitumor effect in SJSA osteosarcoma. 
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was also examined via immunohistochemistry using Ki-67, which is a cellular marker specific for proliferating cells.
At 48 hours after a single dose of RG7388, tumors from treated mice produced a maximal statistically significant induction in luciferase signal (Fig. 5A) When RG7388 was administered for 5 days at 80 mg/kg, the maximal effect on apoptosis via activated caspase 3 and 7 levels versus vehicle control was observed on day 3 ( P < 0.05; Fig. 6A ). Moreover, cPARP-1 levels were highest on day 3 versus vehicle control after 5 days of RG7388 administration (Fig. 6B) . Lastly, with 5 days of administration of RG7388, the maximal decrease in Ki-67 versus vehicle control also occurred on day 3 (P < 0.05; Fig 6C) . Therefore apoptotic and antiproliferative pharmacodynamic effects were comparable with the continuous (80mg/kg daily) and with the single dose (200mg/kg) dosing regimen. This supports our model-based hypothesis that a continuous dosing regimen is not needed. 
Discussion
MDM2 inhibitors can be used in MDM2 gene amplified tumors to restore functional p53 activity. In preclinical models RG7388, a second generation MDM2 inhibitor, has demonstrated the ability to activate apoptosis and induce tumor stasis with continuous treatment (10) . Here, we provide evidence that continuous dosing of RG7388 is not required for sustained activity. Although in vitro apoptotic effects were delayed relative to noncontinuous treatment, once triggered, the p53 pathway activation of apoptosis was irreversible in SJSA1 cells even after drug removal. Interestingly, Western blot analysis showed that p53 levels remained elevated significantly longer than MDM2 and p21 after RG7388 washout. The loss of MDM2 and p21 protein levels could be the result of changes in protein half-life on p53 activation as evidenced in published results where accelerated MDM2 auto-degradation was reported during p53-mediated DNA damage response (17) . However, p53 function and stability may also be tightly controlled by its subcellular localization (18, 19) . Therefore, it is possible that in a cell triggered into apoptosis, nuclear or mitochondrial localized p53 remains fairly stable following RG7388 washout while MDM2 and p21 are accessible to be targeted by the cytoplasmic ubiquitin proteasome pathway. From a molecular stand point, the continued presence of p53 after RG7388 removal may be critical for sustained activity. These observations were also made with RG7112 but necessitated much higher drug concentrations than the more potent RG7388 to retain elevated p53 levels on washout (data not shown). Collectively, our in vitro results support the hypothesis that RG7388 can induce sustained antitumor activity when given on an intermittent dosing schedule. However, as previous studies in 
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a maximal effect at 48 hours. Likewise, a dose predicted as optimal via M&S on a 5-day schedule (80 mg/kg) also activated apoptosis and decreased proliferation, with a maximal effect after 3 days.
RG7112, a cis-imidazoline, and RG7388, a pyrrolidine compound, both bind to MDM2 and prevent the association of MDM2 with p53. While these compounds have a shared mechanism of action and both reversibly bind to MDM2, RG7388 can be used at significantly lower doses due to superior potency and specificity (8, 10) . These superior properties of RG7388 may also allow RG7388 to be dosed intermittently, which should circumvent toxicities associated with prolonged continuous treatment with RG7112 while maintaining clinical benefit. The preclinical data presented herein provide proof of principle that intermittent RG3788 dosing can provide the same activity as daily dosing.
While Response Evaluation Criteria In Solid Tumors responses were achieved in previous RG7112 clinical trials, patients had difficulty tolerating RG7112 given on the requisite daily schedule (9) . Based on those results and on the work presented here, a once weekly × 3 followed by 13 days of rest, 28-day cycle schedule and a 5 consecutive days of a 28-day cycle schedule were utilized for the initial phase I RG7388 clinical trial (trial registration identifier: NCT01462175). The ability to administer RG7388 intermittently should provide better tolerability for patients, which may intern result in more robust clinical responses. Step 1: Design & conduct PKPD experiment
Step 2: PKPD modeling to integrate knowledge, assumptions and data
Step 3: Use the PKPD model to explore "what if" scenarios
Step Research. 
